Abstract Library

#4208 The somatostatin system – A silent messenger in pheochromocytomas and paragangliomas?

Introduction: Pheochromocytomas and paragangliomas (PPGLs) are rare neuroendocrine neoplasms (NENs) arising from neural crest-derived chromaffin cells. Due to the abundance of somatostatin receptors (SSTs) on the surface of most NENs, somatostatin analogues (SSAs) have become a cornerstone in their diagnosis and treatment. However, while PPGLs exhibit this feature, their functional responsiveness to SSAs remains limited, with the underlying cause of this resistance being still elusive.

Conference:

Presenting Author:

Authors: García Vioque V, Moreno-Montilla M, Blázquez-Encinas R, Barlier A, Arroba E,

Keywords: pheochromocytomas, paragangliomas, neuroendocrine tumor, somatostatin analogues, treatment resistance,

#4014 Network pharmacology reveal the mechanism of Cordycepin and neuroendocrine tumors

Introduction: Patients with advanced neuroendocrine tumors (NETs) have few treatment options and poor prognosis. Cordycepin is a natural compound originally isolated from Cor­dyceps militaris. It has the potential to treat cancer by regulating multiple cellular signaling pathways. However, its anticancer effect and pharmacological mechanism in NETs have not been clarified.

Conference:

Presenting Author:

Authors: Liu M, Yan L, Tang Q,

Keywords: Cordycepin, neuroendocrine tumor, network pharmacology, enrichment analysis, Chinese medicine,

#3987 m6A modifications promote the invasion and metastasis of pancreatic neuroendocrine neoplasms by activating the Integrin/FAK signalling pathway via TGFBI

Introduction: Nearly 50% of patients with pNENs have metastases at the time of initial diagnosis, and there is a lack of effective treatment once they have metastases. The 5-year overall survival rate for G3 pNENs with metastasis at diagnosis was 0, which was significantly lower than that for patients without metastasis, with a 5-year overall survival rate of 43%. At present, the pathogenesis of pNENs has not been clarified.

Conference:

Presenting Author:

Authors: Ye M, Tang Q,

Keywords: RNA methyltransferases, Tumor metastasis, Pancreatic neuroendocrine neoplasm, Transforming growth factor-β-induced gene, Integrin/FAK signaling pathway,

#3959 Sortilin: A novel marker and potential therapeutic target for functional neuroendocrine tumors

Introduction: A subset of neuroendocrine tumors (NETs) causes a hormone-related disease (functional syndrome); e.g. carcinoid syndrome due to over-secretion of mainly serotonin. Notably, on a molecular level, what distinguishes this subset of functional NETs from nonfunctional tumors is unknown. Furthermore, accurate models of functional NETs are missing. Sortilin, a widely expressed transmembrane receptor, is expressed in many cancer cells, including NETs, and is involved in secretion processes.

Conference:

Presenting Author: Bolduan F

Authors: Bolduan F, Wetzel A, Giesecke Y, Eichhorn I, Alenina N,

Keywords: Neuroendocrine tumor, Functional syndrome, Carcinoid syndrome, Serotonin, Sortilin, Organoids, Enteroendocrine cells,

#3948 Molecular typing and mutational characterisation of rectal neuroendocrine neoplasms

Introduction: Rectal neuroendocrine neoplasms (NENs) are rare neoplasms with limited understanding of its genomic alterations and molecular typing.

Conference:

Presenting Author:

Authors: Duan X, Yin F,

Keywords: rectal neuroendocrine neoplasms, genomic alterations, molecular typing, signaling pathway, DDR mutant genes,